-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDISIN US64125C1099-
Neurocrine BiosciencesBörse Börse FrankfurtEURSymbol NB3
-
Neurocrine BiosciencesBörse Börse BerlinEURSymbol NB3
-
Neurocrine BiosciencesBörse Börse MünchenEURSymbol NB3
-
NEUROCRINE BIOSCIENCES INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NB3
-
NEUROCRINE BIOSCIENCES INCBörse Börse DüsseldorfEURSymbol NB3
-
NEUROCRINE BIOSCIENCES INCBörse Quotrix System der Börse DüsseldorfEURSymbol NB3
-
NEUROCRINE BIOSCIENCES INCBörse Gettex System der Börse MünchenEURSymbol NB3
-
NEUROCRINE BIOSCIENCES INCBörse Börse StuttgartEURSymbol NB3
-
ISIN US64125C1099 WKN: 900964USDSymbol NBIX
-
USD
-
ISIN US64125C1099
WKN 900964
Symbol NBIX
Währung
USD
Firmenname
Neurocrine Biosciences, Inc
Marktkapitalisierung
8.974.898.432 (+- 14%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
10.197.796.864 oder 7.752.000.000
Mitarbeiter
1.063 (+- 22%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
825 oder 1.300 Mitarbeiter
KGV
113.34
EBITDA 349.107.008
PEGRatio 1.87
Buchwert 8.611
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 78,94 EUR +0,10%
Portrait der Neurocrine Biosciences Aktie
Das Unternehmen Neurocrine Biosciences, Inc aus USA beschäftigt 1.063 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie, Pharma tätig.
Das Unternehmen Neurocrine Biosciences, Inc ist in ungefähr 29 ETFs enthalten und somit eine vermutlich durchschnittlich bekannte Aktie. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet Neurocrine Biosciences mit 1,79% im ETF.
Entdecke die 6 ETFs in denen Neurocrine Biosciences, Inc am höchsten gewichtet ist Insgesamt in 29 ETFs enthalten
Dir gefallen die Informationen zu Neurocrine Biosciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Neurocrine Biosciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Neurocrine Biosciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Neurocrine Biosciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
27 News & Informationen zur Neurocrine Biosciences Aktie
National Pension Service Buys Invesco PureBeta SM MSCI USA ETF, Marvell Technology Inc, Advance Auto Parts Inc, Sells General Electric Co,
GuruFocus Article or News written by insider and the topic is about:
PFM Health Sciences, LP Buys Seagen Inc, Centene Corp, ACADIA Pharmaceuticals Inc, Sells PPD Inc, Jaws Acquisition Corp, Insulet Corp
GuruFocus Article or News written by insider and the topic is about:
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis …
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase stimulator for the treatment of neurological diseases associated with… | July 29, 2021
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idorsia : Media Release (English)
Media Release
July 27, 2021
Ad hoc announcement pursuant to Art. 53 LR
Idorsia announces financial results for the… | July 27, 2021
Press Release : Idorsia announces financial results for the first half 2021 — Building momentum towards becoming a fully-fledged biopharmaceutical company
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland — July 27, 2021
Idorsia Ltd today announced its financial results for the first half of 2021.
Business highlights
… | July 27, 2021
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021Idorsia Ltd today announced its financial results for the first half of 2021. Business highlights … | July 27, 2021
Neurocrine Biosciences/The Harris Poll Survey: 8 in 10 Americans Will Always Prefer In-Person Doctor Appointments to Telehealth
PDF Version
Patients Overall Satisfied with Telehealth Care Received During the Pandemic but also Worry Things Will Be Missed on Telehealth
SAN DIEGO,… | July 22, 2021
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the…
Here is What Hedge Funds Think About Jones Lang LaSalle Inc (JLL)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors…
Hedge Funds Are Crazy About BridgeBio Pharma, Inc. (BBIO)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Neurocrine Biosciences : to Participate at the William Blair Biotech Focus Conference
SAN DIEGO, July 8, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a… | July 8, 2021
10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
In this article, we will discuss the 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. If you want to skip our detailed analysis…
Sarepta, Vertex, Neurocrine: There’s Deep Value In These Beaten Down Healthcare Stocks
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years…
BofA Securities Makes Big Summer Changes to US 1 List of Top Stock Picks – 24
The analysts at BofA Securities have made some big changes to the firm's US 1 list of top stock recommendations. FedEx stock was added, and four that have performed admirably were removed.
Hedge Funds Are Nibbling On Sensata Technologies Holding plc (ST)
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending,…
Retirement Systems of Alabama Buys Lowe's Inc, Wells Fargo, Vertex Pharmaceuticals Inc, Sells The Home Depot Inc, Walmart Inc, Johnson & Johnson
Retirement Systems of Alabama Buys Lowe's Inc, Wells Fargo, Vertex Pharmaceuticals Inc, Sells The Home Depot Inc, Walmart Inc, Johnson & Johnson, Stocks: LOW,WFC,VRTX,CMCSA,DHR,EL,KDP,CPRI,NXPI,WD5A,CLF,N, release date:Apr 15, 2021
Neurocrine Biosciences Preliminary Full-Year INGREZZA Net Product Sales Up 32%
(RTTNews) – Neurocrine Biosciences, Inc. (NBIX) said, based on preliminary unaudited financial information, the company expects INGREZZA net produ…
EDGAR Filing Documents for 0000914475-21-000004
Neurocrine Biosciences : Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ –?Neurocrine Biosciences, Inc. today provided an update on its business performance, including preliminary net product and inventory adjusted sales… | January 8, 2021
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today provided an update on its business performance, including …
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, includin…
Get Ready For Health Care Stocks to Go Wild. How to Play Them.
Politics is the hot story of January, but health care might be the hot trade.
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on…
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, partly due to Covid-19 related disruptions of the health care industry…